Illuminating Lymphatics: Ankyron® CJ30451 Reveals LYVE1 with Unmatched Precision

ProImmune is spotlighting the capabilities of its next-generation recombinant binding reagent, Ankyron® clone CJ30451, in a recent visualization of LYVE1, a key lymphatic vessel marker.

Using fluorescence microscopy, LYVE1 was detected in cyan at the overlapping flaps of endothelial cell junctions in skin tissue. The breakthrough lies in the ultra-compact size of Ankyrons—approximately one-tenth the size of traditional monoclonal antibodies (~15 kDa)—which allows them to navigate and label tight cellular junctions with high precision. This enables detailed mapping of endothelial structures previously difficult to access.

LYVE1, beyond its structural role, serves as a crucial gatekeeper for immune surveillance and cancer metastasis, binding to hyaluronan on immune and tumor cells to facilitate their entry into the lymphatic system.

The image was captured using ProImmune’s trusted DiscoverEcho microscope platform, underscoring the synergy between advanced imaging and molecular targeting tools.

Importantly, Ankyrons are 100% animal-free, offering a sustainable and ethical alternative for researchers in immunology, oncology, and vascular biology.

Learn more about Ankyrons here.